When prescribing inhalers the drug, device (e.g. MDI, Easibreathe, Autohaler, Accuhaler), strength (micrograms per inhalation), number of puffs per dose and frequency MUST be specified

If you are prescribing any spacer device to a patient for the first time, these patients should be monitored frequently in the normal way for the emergence of or worsening of symptoms of disease or adverse effects. Any patients who are switched to a different device should be regarded in the same way as new patients, and the same careful monitoring is required.
For inhaled ß2 agonist bronchodilators the most frequent signs of toxicity are headache, tremor and palpitations;
for inhaled corticosteroids the most serious concern from over exposure is adrenal suppression and particularly when high doses are administered to children and adolescents.

• Key
• Full Site